brain cancer

[Nature Cancer] Investigators review recent advances and ongoing challenges in pediatric brain cancer immunotherapy, as well as considerations for efficient clinical translation of efficacious immunotherapies into pediatric settings.

[Cell Death & Disease] The authors revealed crucial roles and a novel mechanism of poly ε-B subunit (POLE2) involved in glioblastoma (GBM) through Aurora kinase A (AURKA)-mediated stability of forkhead transcription factor (FOXM1) and may provide the theoretical basis of molecular therapy for GBM.

[Cancer Discovery] Researchers interrogated gene expression and whole-genome CRISPR/Cas9 screening in a large panel of patient-derived glioblastoma (GBM) stem cells (GSCs), differentiated GBM cells, and neural stem cells to identify master regulators of GSC stemness.

[NOXXON Pharma N.V.] NOXXON Pharma N.V. announced that the Data Safety Monitoring Board positively evaluated safety data from the initial four weeks of treatment of the first patient enrolled in the GLORIA clinical trial expansion arm.

[Photodiagnosis and Photodynamic Therapy] Scientists present a brief review exclusively commenting on the therapeutic approaches to eliminate glioblastoma stem cells and on the research publications about this topic of glioblastoma stem cells in relation to photodynamic therapy.

[NOXXON Pharma N.V.] NOXXON Pharma N.V. announced that the first patient was enrolled in an expansion arm of the GLORIA clinical trial of NOX-A12 in MGMT unmethylated brain cancer.